XML 72 R38.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Investment in Joint Ventures (Details Textual) (USD $) | 3 Months Ended | 12 Months Ended | 0 Months Ended |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2014 Instruments | Dec. 31, 2013 | Jun. 30, 2014 | Mar. 31, 2013 | Mar. 31, 2011
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Joint venture owned by the entity | 49.98%us-gaap_EquityMethodInvestmentOwnershipPercentage |  | 49.98%us-gaap_EquityMethodInvestmentOwnershipPercentage |  |  |  |
Sale of stock, price per share | $ 0.45 us-gaap_SaleOfStockPricePerShare |  | $ 0.45 us-gaap_SaleOfStockPricePerShare |  |  |  |
Purchase of additional shares | 995,000 us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions |  |  |  |  |  |
Purchase of additional shares, value | $ 447,750 us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions |  |  |  |  |  |
Investment in Milestone Medical Inc | 888,720 us-gaap_CostMethodInvestments |  | 888,720 us-gaap_CostMethodInvestments |  |  |  |
Chief Executive Officer |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Loan from parent company CEO |  |  |  |  |  | 50,000 us-gaap_DueToOfficersOrStockholdersCurrent / us-gaap_TitleOfIndividualAxis = us-gaap_ChiefExecutiveOfficerMember |
Medical Joint Venture |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Contribution of Milestone in joint venture |  |  | 1,500,000 us-gaap_TechnologyServicesCosts / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Instrument inception period |  |  | 30 months |  |  |  |
Contingency associated with the return of capital to Beijing 3H | 0 us-gaap_LossContingencyAccrualCarryingValueCurrent / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  | 0 us-gaap_LossContingencyAccrualCarryingValueCurrent / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Capital contribution | 1,500,000 us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  | 1,500,000 us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Joint venture owned by the entity |  |  |  |  |  |  | 50.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember
Contribution of Milestone in joint venture | 349,000 us-gaap_FiniteLivedLicenseAgreementsGross / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  | 349,000 us-gaap_FiniteLivedLicenseAgreementsGross / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Number Of Development Of Instruments |  |  | 2 mlss_NumberOfDevelopmentOfInstruments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Sale of stock, number of shares |  | 2,000,000 us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |  |
Sale of stock, price per share | $ 0.45 us-gaap_SaleOfStockPricePerShare / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | $ 1.50 us-gaap_SaleOfStockPricePerShare / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | $ 0.45 us-gaap_SaleOfStockPricePerShare / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | $ 1.50 us-gaap_SaleOfStockPricePerShare / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Sale of stock, value |  | 3,000,000 us-gaap_SaleOfStockConsiderationReceivedOnTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |  |
Net proceeds received in joint venture |  | 2,363,000 us-gaap_ProceedsFromIssuanceOrSaleOfEquity / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |  |
Percentage of ownership after transaction | 49.98%us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  | 49.98%us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | 50.00%us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Purchase of additional shares | 995,000 us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |  |  |
Purchase of additional shares, value | 447,750 us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |  |  |
Loss on Earnings from joint venture |  |  | (891,500)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | (924,363)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Legal expenses related to marketing clearance |  |  | 249,966 us-gaap_LegalFees / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | 225,979 us-gaap_LegalFees / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Reimbursable expense included in account receivable, net | 125,144 us-gaap_AccountsReceivableRelatedParties / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  | 125,144 us-gaap_AccountsReceivableRelatedParties / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |  |
Loss on Joint Ventures |  |  | (1,896,784)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | (1,019,606)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Investment in joint venture | 888,720 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | 924,115 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | 888,720 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember | 924,115 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember |  |  |
Medical Joint Venture | 2013 Operations |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Loss on Earnings from joint venture |  |  |  | (509,803)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember / us-gaap_StatementOperatingActivitiesSegmentAxis = mlss_OperationsMember |  |  |
Medical Joint Venture | Private Placement |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Percentage of ownership before transaction |  | 50.00%us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember |  |  |  |  |
Percentage of ownership after transaction |  | 45.50%us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember |  |  |  |  |
Gain on dilution effect |  | 1,363,650 us-gaap_GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_MedicalJointVentureMember / us-gaap_SubsidiarySaleOfStockAxis = us-gaap_PrivatePlacementMember |  |  |  |  |
Education Joint Venture |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Loss on Earnings from joint venture |  |  | (17,890)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | (7,918)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember |  |  |
Loss on Joint Ventures |  |  | 35,779 us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | 15,836 us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember |  |  |
Percentage of gain/loss on joint venture |  |  | 50.00%mlss_EquityMethodInvestmentSummarizedFinancialInformationPercentageOfNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | 50.00%mlss_EquityMethodInvestmentSummarizedFinancialInformationPercentageOfNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember |  |  |
Investment in joint venture | 24,192 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | 42,082 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | 24,192 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember | 42,082 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = mlss_EducationJointVentureMember |  |  |
Milestone China |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Joint venture owned by the entity |  |  |  |  | 40.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |
Loss on Joint Ventures |  |  | (810)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  | (2,025)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |
Percentage of gain/loss on joint venture |  |  | 40.00%mlss_EquityMethodInvestmentSummarizedFinancialInformationPercentageOfNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |  |  |
Investment in joint venture | 348,651 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  | 348,651 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  | 1,000,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |
Distributor price per instrument |  |  |  |  | $ 1,295 mlss_DistributorPricePerInstrument / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |
Milestone China | Net Income Loss |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |
Loss on Joint Ventures |  |  | $ (2,025)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_IncomeStatementLocationAxis = mlss_NetIncomeLossMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |  |  |  |

X
- Definition Distributor price per instrument. + References No definition available. + Details
Name: | mlss_DistributorPricePerInstrument
Namespace Prefix: | mlss_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity method investment summarized financial information percentage of net income loss. + References No definition available. + Details
Name: | mlss_EquityMethodInvestmentSummarizedFinancialInformationPercentageOfNetIncomeLoss
Namespace Prefix: | mlss_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Instrument development period from inception date. + References No definition available. + Details
Name: | mlss_InstrumentDevelopmentPeriodFromInceptionDate
Namespace Prefix: | mlss_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of development of instruments. + References No definition available. + Details
Name: | mlss_NumberOfDevelopmentOfInstruments
Namespace Prefix: | mlss_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, amount of receivables arising from transactions with related parties. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),3) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 3 -Article 7 + Details
Name: | us-gaap_AccountsReceivableRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 325 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 325 -SubTopic 20 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=29638308&loc=d3e40346-111594 + Details
Name: | us-gaap_CostMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 12 -Subparagraph a(1) -Article 6 + Details
Name: | us-gaap_DueToOfficersOrStockholdersCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of net income (loss) reported by an equity method investment of the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(g)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33912-111571 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph bb -Article 1 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph g -Subparagraph 1, 2 -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph w -Article 1 + Details
Name: | us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedLicenseAgreementsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The profit or loss on sales of previously unissued stock by subsidiaries or equity investees made to investors outside the consolidated group that is not reported as operating income. Represents the difference in the parent company's carrying amount of the equity interest in the subsidiary or equity investee immediately before and after the transaction. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.13(g)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Subparagraph h -Article 9 + Details
Name: | us-gaap_GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.12) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualCarryingValueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amounts due from owners or affiliates of the reporting entity related to issuance of the entity's capital stock before cash payment is received (does not include amounts due from officers or directors). This element would also include the receivable for proceeds from the issuance of shares under employee stock option exercises which proceeds have not been received as of the reporting date due to the timing of the transaction date versus the settlement date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29,30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions. + References No definition available. + Details
Name: | us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative amount of cash and other consideration received by subsidiary or equity method investee in exchange for shares or stock issued or sold. Include amounts of cash received, fair value of non-cash assets received, fair value of liabilities assumed, and fair value of any other forms of consideration. + References No definition available. + Details
Name: | us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 605 -Section 25 -Paragraph 76 -URI http://asc.fasb.org/extlink&oid=22169047&loc=d3e132428-111767 + Details
Name: | us-gaap_TechnologyServicesCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_EducationJointVentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MedicalJointVentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |